Correction to: British Journal of Cancer (2014) 111, 1909–1916. doi:10.1038/bjc.2014.503
During the final correction process of this paper, the affiliation for Dr AB Suttle was mistakenly applied to two other authors. The full, correct author listing and affiliations are now listed above. The publishers apologise for this error.
Change history
09 December 2014
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Author information
Authors and Affiliations
Additional information
The online version of the original article can be found at 10.1038/bjc.2014.503
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Suttle, A., Ball, H., Molimard, M. et al. Erratum: Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 111, 2383 (2014). https://doi.org/10.1038/bjc.2014.627
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2014.627
This article is cited by
-
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
Cancer Chemotherapy and Pharmacology (2017)
-
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
Clinical Pharmacokinetics (2017)
